- 专利标题： 2-METHYL-QUINAZOLINES
-
申请号： US16496825申请日： 2018-03-19
-
公开(公告)号： US20220235013A1公开(公告)日： 2022-07-28
- 发明人: Lars WORTMANN , Brice SAUTIER , Knut EIS , Hans BRIEM , Niels BOHNKE , Franz VON NUSSBAUM , Roman HILLIG , Benjamin BADER , Jens SCHRODER , Kirstin PETERSEN , Philip LIENAU , Antje Margret WENGNER , Dieter MOOSMAYER , Qiuwen WANG , Hans SCHICK
- 申请人： BAYER PHARMA AKTIENGESELLSCHAFT
- 申请人地址： DE Berlin
- 专利权人： BAYER PHARMA AKTIENGESELLSCHAFT
- 当前专利权人： BAYER PHARMA AKTIENGESELLSCHAFT
- 当前专利权人地址： DE Berlin
- 优先权： CNPCT/CN2017/077501 20170321
- 国际申请： PCT/EP2018/056824 WO 20180319
- 主分类号： C07D239/94
- IPC分类号： C07D239/94 ; C07D409/12 ; C07D405/12 ; C07D403/12 ; C07D417/12 ; C07D471/04 ; C07D413/12 ; C07D401/12 ; C07D409/14 ; C07D413/14
摘要：
The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions.
The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.
The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.
信息查询
